The efficacy and safety of paclitaxel liposomes in the treatment of 30 patients with non-small cell lung cancer

Objective:To compare the efficacy and safety of domestic-made paclitaxel liposomes with paclitaxel in the treatment of non-small cell lung cancer(NSCLC).Methods:Sixty-two patients with advanced NSCLC were prospectively randomized into two groups,experimental group given paclitaxel liposome at 135mg/m2 each cycle,and control group given paclitaxel at 135mg/m2.Both groups combined with CBP at 300mg/m2 per cycle every three weeks.The efficacy and safety were evaluated after two cycles.Results:Sixty-two patients were enrolled into this study.Thirty patients and 32 patients were enrolled into the experimental group and the control respectively.There were 60 eligible patients for the analysis of overall response rate.The overall response rate was 26.7% in the experimental group and 23.3% in the control group.There was no significant difference between the two groups.Though there was no significant difference in hematological toxicity and most of non-hematological toxicity between the two groups,peripheral neuritis and the toxicity from the mixed solvent of polyethoxylated castor oil and ethanol were significantly lower in the experimental group than those in the control group.Conclusion:Paclitaxel liposome combined with CBP in the treatment of advanced NSCLC can significantly reduce the incidence of peripheral neuritis and serious hypersensitive reactions and has a the similar response rate as that of paclitaxel.